Table 1.
Baseline demographic data
| Total (n=32) | Control (n=13) | PDT+ranibizumab (n=8) | Aflibercept (n=11) | |
|---|---|---|---|---|
| Age (years) | 79.79 | 79.99 | 77.63 | 77.93 |
| Sex, male (%) | 19 (59) | 8 (61.5) | 5 (62.5) | 6 (54.5) |
| Ethnicity | ||||
| Caucasian (%) | 13 (41) | 4 (31) | 4 (50) | 5 (45) |
| Asian (%) | 19 (59) | 9 (69) | 4 (50) | 6 (55) |
| Type of AMD | ||||
| Occult (%) | 21 (65.7) | 8 (61.5) | 4 (50) | 9 (81.8) |
| Minimally classic (%) | 4 (11.4) | 0 | 2 (25) | 2 (18.2) |
| Predominantly classic (%) | 7 (21.9) | 5 (28.5) | 2 (25) | 0 |
| Baseline BCVA (logMar) | 0.79 | 0.87 | 0.78 | 0.83 |
| Baseline CST (μm) | 287.75 | 232.46 | 335.75 | 318.18 |
Abbreviations: AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; CST, central subfield thickness; PDT, photodynamic therapy.